In UK population data, Black men, particularly those of African and Caribbean ancestry, have the highest reported lifetime risk of prostate cancer. Prostate Cancer UK estimates that around 1 in 4 Black men will be diagnosed during their lifetime, approximately twice the risk reported for other men. Prostate cancer incidence is lower among Asian men than among White men.
Black men are also more likely to be diagnosed at a younger age. The reasons for these differences are not fully understood and are likely to involve a combination of inherited biology, patterns of PSA testing, access to healthcare and wider social factors. No single genetic, biological or social explanation accounts for the difference.
These figures describe population-level patterns and cannot predict what will happen to you personally. Understanding your ethnicity alongside your age, family history and any confirmed genetic risk can help you make an informed decision about PSA testing and further assessment.
Understanding How Ethnicity Affects Prostate Cancer Risk
Prostate cancer can affect people from every ethnic background, but reported incidence varies between population groups. These differences may involve the age at diagnosis, patterns of testing, access to care and other health or social factors.
Understanding these population-level differences can support informed conversations about your personal risk. It may help you decide when to discuss PSA testing, family history or genetic assessment with your GP or specialist.
Ethnicity should never be considered on its own. Age, family history and confirmed pathogenic genetic variants are important risk factors. Body weight and general health may influence some outcomes, but no lifestyle change can remove inherited risk or guarantee that prostate cancer will be prevented.
Why Black Men Have a Higher Reported Risk of Prostate Cancer
Black men have a higher reported incidence of prostate cancer in the UK and may be diagnosed at a younger age than men from several other ethnic groups. However, the reasons for this difference remain incompletely understood.
Inherited genetic ancestry may contribute, but no single gene or genetic variant explains the higher population-level risk. Routine germline genetic testing is not recommended solely because someone is Black. Access to healthcare, trust in health services, patterns of PSA testing and referral pathways may influence diagnosis and outcomes. Underrepresentation in research can also limit the evidence available to guide screening, risk prediction and care for Black men.
The practical implication is not that every Black man needs the same investigation pathway. It means that prostate cancer risk and the potential benefits and limitations of PSA testing should be discussed proactively, particularly from age 45 or when there is also a relevant family history.
The Role of Genetics in Ethnic Differences
Genes can influence prostate cancer risk, and some inherited variants are more common in particular populations. However, ethnicity cannot tell you whether you carry a specific genetic variant. Your ancestry, family history and any confirmed genetic result should be considered together when discussing PSA testing, genetic counselling and follow-up.
Risk Factors and Their Practical Implications
| Risk factor | What current evidence suggests | Practical next step |
| Black African or Caribbean ancestry | Black men have the highest reported lifetime risk in UK data and may be diagnosed younger | Discuss individual PSA testing from age 45 after reviewing the benefits and limitations |
| Ashkenazi Jewish ancestry | Certain founder BRCA1 and BRCA2 variants are more common, but ancestry alone does not establish prostate cancer risk | Consider genetic advice if you have a relevant personal or family history |
| Close family history | Risk may be higher if a father or brother had prostate cancer, particularly if that relative was diagnosed before age 60. | Discuss individual PSA testing from age 45 and whether genetic assessment is appropriate |
| Pathogenic BRCA2 variant | BRCA2 is associated with an increased likelihood of clinically significant prostate cancer | Ask about risk-based surveillance and current UK screening eligibility |
| Increasing age | Age is one of the strongest risk factors, with most cases occurring after 50 | Consider age, health, life expectancy and personal preferences when discussing PSA testing |
Prostate Cancer Risk Among Ashkenazi Jewish Men
Having Ashkenazi Jewish ancestry does not confirm that you carry a pathogenic BRCA variant or that your personal prostate cancer risk is increased. However, certain founder variants in BRCA1 and BRCA2 are more common in people with this ancestry.
The association with prostate cancer is strongest for pathogenic BRCA2 variants, which may be linked with younger diagnosis and more clinically significant disease. The association between BRCA1 and prostate cancer is less clear and appears to be smaller.
Carrying a pathogenic BRCA variant does not mean that cancer is present or inevitable. The implications for prostate cancer depend on the gene involved and are strongest for BRCA2. A variant of uncertain significance should not normally be treated as proof of increased risk without specialist interpretation.
Genetic advice may be appropriate if you have a close relative with a confirmed BRCA variant or a family history of prostate, breast, ovarian or pancreatic cancer. As of July 2026, the NHS Jewish BRCA Testing Programme is closed to new registrations following completion of its pilot. NHS England is working to establish a longer-term service anticipated in 2027. People with a relevant personal or family history may still qualify for genetic testing through another NHS clinical genetics pathway.
How Family History Changes Your Risk
Your family history is one of the most important factors when understanding your prostate cancer risk. If your father, brother or another close relative has had prostate cancer, you may have a higher chance of developing the disease yourself. This is especially relevant if relatives were diagnosed at a younger age.
It is not only prostate cancer that can provide important clues about inherited risk. A family history of breast cancer, ovarian cancer or pancreatic cancer may also suggest the presence of shared genetic factors. These patterns can help your doctor understand whether further assessment may be appropriate.
By sharing your family history with your healthcare team, you can support a more personalised approach to PSA testing, genetic assessment and follow-up. This information can help guide discussions about genetic testing and the most suitable next steps for your prostate health.
When Should Higher-Risk Men Discuss PSA Testing?
The PSA blood test measures prostate-specific antigen, which may be raised by prostate cancer, an enlarged prostate, inflammation or infection. It cannot diagnose prostate cancer by itself, but it can help identify when further assessment may be appropriate.
European guidance recommends offering informed early PSA testing from age 45 to men of African descent and to men whose family history includes prostate cancer diagnosed before age 60. It recommends discussion from age 40 for men with a pathogenic BRCA2 variant. These are individual early-detection recommendations rather than a national UK screening programme.
UK Guidance Note
Following its March 2026 review, the UK National Screening Committee did not recommend population-wide prostate cancer screening or targeted screening for Black men solely because of ethnicity. The committee concluded that there is still insufficient evidence to determine whether formal screening of Black men would provide more benefit than harm.
The UK NSC’s targeted screening recommendation applies to men aged 45 to 61 who have a pathogenic BRCA2 variant and a family history of breast, ovarian, pancreatic or prostate cancer. The programme will involve PSA testing every two years. The recommendation has been accepted for implementation in England, with rollout expected to begin in 2027. Implementation and patient-identification arrangements are still being developed.
The absence of a national screening recommendation does not prevent you from discussing an individual PSA test. If you are a Black man aged 45 or over, you can speak with your GP about your risk and the potential advantages and disadvantages of testing, even if you do not have symptoms.
Understanding PSA Testing and Its Limitations
A raised PSA result does not automatically mean that you have prostate cancer. PSA can also increase because of benign prostate enlargement, inflammation, infection, recent prostate procedures and other factors. Conversely, some clinically significant prostate cancers do not produce a clearly raised PSA.
PSA testing can lead to false-positive results, further investigations when cancer is not present and the diagnosis of slow-growing cancers that would never have caused harm. This can expose some men to anxiety, biopsy risks or treatment side effects unnecessarily.
If your PSA is higher than expected, the appropriate next step depends on the result, symptoms, age and overall risk. Your doctor may repeat the PSA test in selected circumstances, refer you to a specialist or arrange multiparametric MRI. Not every raised result follows exactly the same pathway.
How Age Influences Prostate Cancer Risk
Your age is one of the biggest risk factors for prostate cancer, regardless of your ethnic background. The likelihood of developing prostate cancer generally increases as you get older, which is why it may become more important to discuss symptoms, risk factors and the potential benefits and limitations of PSA testing with your doctor.
Black men may be diagnosed with prostate cancer at a younger age than men from several other ethnic groups, which is why individual risk discussions commonly begin from age 45. Age alone should not determine testing; your overall health, life expectancy, family history and preferences should also be considered.
By discussing your age, ethnicity, family history and other risk factors with your doctor, you can better understand when PSA testing may be appropriate. A personalised approach helps ensure that testing and follow-up decisions are based on your individual health needs rather than age alone.
The Impact of Healthcare Access and Awareness
Differences in prostate cancer outcomes are not explained by biology alone. Access to primary care, trust in health services, socioeconomic circumstances, awareness, referral patterns and timely access to diagnostic tests may all contribute to inequalities between communities.
Understanding your risk factors and discussing any symptoms, family history or concerns with a healthcare professional can support timely and appropriate decisions about PSA testing and further assessment.
Lifestyle Factors and Prostate Health
Lifestyle changes cannot remove ethnicity-related or inherited risk, and no diet or exercise programme can guarantee that prostate cancer will be prevented. Healthy habits can nevertheless support your general health and help you remain fit for investigations or treatment if these are ever needed.
- Healthy weight: Maintaining a healthy weight supports cardiovascular and metabolic health and may be particularly relevant to general treatment fitness.
- Regular activity: Physical activity can improve strength, mobility, mood and overall wellbeing.
- Balanced diet: A varied diet containing vegetables, fruit, whole grains and appropriate sources of protein supports general health.
- Avoiding smoking: Not smoking reduces the risk of several serious diseases and supports overall health.
- Risk discussions: Continue any PSA testing or specialist follow-up agreed with your healthcare team.
These measures should complement rather than replace appropriate medical assessment. Speak with your GP if you have symptoms or are concerned about your age, ethnicity, family history or genetic risk.
Can Genetic Testing Help Assess Prostate Cancer Risk?
Genetic testing is not routinely recommended solely because of ethnicity. It may be considered if you have a confirmed pathogenic variant in your family, several close relatives with prostate or related cancers, a prostate cancer diagnosis at an unusually young age, or particular high-risk or metastatic disease characteristics.
Germline testing usually uses a blood or saliva sample to look for inherited pathogenic variants. A positive result can indicate increased risk and may influence follow-up, but it does not diagnose prostate cancer or show that cancer will definitely develop. A variant of uncertain significance should not normally change care without specialist interpretation.
Results may also be relevant to close relatives because inherited variants can be passed through families. Genetic counselling can help you understand the possible results, emotional implications and appropriate next steps.
How Genetic Information Can Influence Treatment Decisions
If prostate cancer is diagnosed, clinicians may consider germline testing, which looks for inherited variants in blood or saliva, and somatic testing, which looks for changes within the cancer itself. The appropriate test depends on the stage and characteristics of the disease.
In adults with metastatic castration-resistant prostate cancer and a BRCA1 or BRCA2 mutation, olaparib may be an option when the cancer has progressed after treatment with a newer hormonal medicine such as abiraterone or enzalutamide. Eligibility also depends on previous treatment, disease stage, overall health and current NICE guidance.
Your specialist can explain whether genetic testing is relevant to treatment or whether the information is primarily useful for assessing inherited risk and advising family members.
Myth vs Fact
| Myth | Fact |
| Being Black means you will definitely develop prostate cancer. | Black men may have a higher risk of prostate cancer, but ethnicity alone does not determine whether you will develop the disease. |
| Prostate cancer only affects older men. | Risk increases with age, but some higher-risk groups may develop prostate cancer at a younger age. |
| Ethnicity is the only reason some groups have higher prostate cancer rates. | Differences in risk are linked to a combination of genetics, biology, healthcare access, awareness and other factors. |
| A family history of prostate cancer does not matter if you are healthy. | A strong family history can increase your risk and may mean you should discuss earlier PSA testing or genetic assessment. |
| A normal PSA test means you cannot have prostate cancer. | PSA testing is useful but cannot detect every case of prostate cancer. Your results should be considered alongside other risk factors. |
| Pathogenic genetic variants always lead to prostate cancer. | Pathogenic variants can increase risk but do not mean that prostate cancer is present or inevitable. |
| Men from lower-risk ethnic groups do not need to think about prostate health. | Prostate cancer can affect men from all backgrounds, and awareness of symptoms and risk factors remains important. |
| Black men are automatically included in a national prostate cancer screening programme. | The UK NSC does not currently recommend targeted national screening based on Black ethnicity alone. Black men can still discuss individual PSA testing from age 45 after reviewing the benefits and limitations. |
Symptoms of Prostate Cancer You Should Know
Early prostate cancer often causes no noticeable symptoms. Urinary changes such as difficulty starting to urinate, a weaker flow or needing to urinate more often are commonly caused by benign prostate enlargement, but new, persistent or worsening symptoms should still be assessed.
Speak with a GP if you notice urinary changes, blood in your urine or semen, unexplained weight loss, erectile difficulties or persistent lower-back, hip or bone pain. These symptoms have many possible causes and do not automatically mean that you have prostate cancer.
Ask for an urgent GP appointment or contact NHS 111 if you see blood in your urine, even if it happens only once. Contact NHS 111 urgently if you cannot pass urine. Call 999 or go to A&E immediately if back pain is accompanied by weakness or numbness in both legs, loss of sensation around the genitals or anus, or changes in bladder or bowel control.
The Role of Specialist Advice for Higher-Risk Men
If you have several risk factors, a strong family history, a confirmed pathogenic variant, an abnormal PSA result or concerning symptoms, your GP can advise whether referral to urology or clinical genetics is appropriate.
A specialist can review your family history and test results, explain the benefits and limitations of PSA testing, and discuss whether MRI, genetic counselling or another assessment is needed. Not everyone at increased risk requires immediate specialist investigation.
How Research Is Improving Understanding of Ethnic Risk Factors
Researchers are continuing to investigate why Black men have a higher reported incidence of prostate cancer and whether specific early-detection strategies provide more benefit than harm. This work includes genetics, diagnostic testing, healthcare inequalities and the accuracy of risk-prediction tools in men of African and Caribbean ancestry.
The UK TRANSFORM trial is evaluating different approaches to prostate cancer early detection. Following additional government investment announced in June 2026, stage 2 is expected to invite eligible Black men aged 45 to 74 who live in the UK and have not had a PSA test or prostate MRI scan during the previous five years, subject to successful stage 1 outcomes.
This research is particularly important because the UK NSC concluded in 2026 that there was not yet enough evidence to recommend targeted national screening for Black men. Future trial results may therefore influence how UK guidance develops.
Key Takeaways
- In UK data, Black men, particularly those of African and Caribbean ancestry, have the highest reported lifetime risk of prostate cancer.
- Around 1 in 4 Black men may be diagnosed, although population statistics cannot predict your individual outcome.
- Black men can discuss individual PSA testing from age 45, but the UK NSC does not currently recommend a national screening programme based on Black ethnicity alone.
- The UK NSC has recommended targeted PSA screening every two years for men aged 45 to 61 who have a pathogenic BRCA2 variant and a relevant family history. In England, the programme is expected to begin rolling out in 2027.
- Ashkenazi Jewish ancestry increases the likelihood of carrying certain BRCA founder variants, but ancestry alone does not determine prostate cancer risk.
- Age, family history and confirmed pathogenic variants should be considered alongside ethnicity.
- PSA testing has potential benefits and limitations, including false-positive and false-negative results, overdiagnosis and potentially unnecessary investigations or treatment.
- Healthy habits support general wellbeing but cannot remove inherited risk or guarantee prostate cancer prevention.
Frequently Asked Questions
1. Which ethnicity has the highest risk of developing prostate cancer?
In UK population data, Black men, particularly those of African and Caribbean ancestry, have the highest reported lifetime risk of prostate cancer. Around 1 in 4 Black men may be diagnosed. Asian men have a lower reported incidence than White men. These figures describe population groups and do not predict your personal outcome.
2. Why are Black men at a higher risk of prostate cancer?
The higher risk among Black men is thought to be linked to a combination of genetic, biological, social and healthcare factors. Inherited genetic ancestry may contribute to differences in risk, but no single gene or genetic variant explains the higher population-level risk among Black men. However, genetics alone do not explain all differences in risk. Access to healthcare, patterns of PSA testing and awareness may also contribute.
3. Does your ethnicity determine whether you will develop prostate cancer?
No, your ethnicity does not determine whether you will develop prostate cancer. It is one part of your overall risk profile, alongside factors such as your age, family history and any confirmed inherited genetic variants. Many men from higher-risk ethnic groups will not develop prostate cancer. Understanding your risk helps you make informed decisions about PSA testing, genetic assessment and follow-up.
4. Should Black men discuss PSA testing earlier?
Black men can discuss PSA testing from age 45, even without symptoms, after receiving balanced information about its benefits and limitations. This is individual early detection rather than a formal national screening programme. The UK NSC does not currently recommend targeted screening based on Black ethnicity alone because the balance of benefits and harms remains uncertain.
5. How can Ashkenazi Jewish ancestry affect prostate cancer risk?
Ashkenazi Jewish ancestry increases the likelihood of carrying certain founder BRCA1 or BRCA2 variants, but ancestry alone does not establish that your prostate cancer risk is higher. The association is strongest for pathogenic BRCA2 variants, which are linked with an increased likelihood of clinically significant prostate cancer. The BRCA1 association is less clear. Genetic counselling can help interpret your personal and family history.
6. How does family history affect your prostate cancer risk?
Your family history can provide important information about your likelihood of developing prostate cancer. If your father, brother or another close relative has had prostate cancer, especially at a younger age, your risk may be higher. Other cancers in your family, such as breast, ovarian or pancreatic cancer, may also provide clues about inherited risks. Sharing this information with your doctor can help guide decisions about PSA testing and genetic assessment.
7. When should you consider genetic testing for prostate cancer risk?
Genetic testing may be considered if a close relative has a confirmed pathogenic variant, several relatives have had prostate, breast, ovarian or pancreatic cancer, or you have particular clinical features after a prostate cancer diagnosis. Testing should be accompanied by appropriate counselling because a pathogenic result, negative result and variant of uncertain significance have different implications.
8. Can a healthy lifestyle prevent prostate cancer?
There is no proven lifestyle strategy that guarantees prostate cancer prevention or removes inherited or ethnicity-related risk. Maintaining a healthy weight, remaining active, avoiding smoking and eating a balanced diet can support your general health and may help you remain well enough for future investigations or treatment.
9. What symptoms of prostate cancer should you be aware of?
Early prostate cancer often causes no symptoms. Speak with a GP about persistent urinary changes, blood in your semen, unexplained weight loss or persistent back or bone pain. Ask for an urgent GP appointment or contact NHS 111 if you see blood in your urine, even if it happens only once. Contact NHS 111 urgently if you cannot pass urine. Call 999 or go to A&E immediately if back pain is accompanied by weakness or numbness in both legs, loss of sensation around the genitals or anus, or changes in bladder or bowel control.
10. What should you do if you are concerned about your prostate cancer risk?
If you are concerned about your risk, you should discuss your ethnicity, family history and any other risk factors with your doctor. They can help you understand whether PSA testing, genetic assessment or specialist referral may be appropriate after a balanced discussion of the benefits and limitations. Taking a proactive approach does not mean you will develop prostate cancer. It simply helps you make informed decisions about your long-term prostate health.
Final Thoughts: Taking a Personalised Approach to Prostate Health
Black men have the highest reported prostate cancer risk in UK population data, but ethnicity is only one part of your personal risk. Your age, family history, genetic results, general health and preferences should all be considered when deciding whether PSA testing or further assessment is appropriate.
If you are concerned about prostate symptoms, your family history or a PSA result, you can contact Prostate Clinic London for an individual assessment and advice about appropriate next steps.
References
- Prostate Cancer UK (2026) Black men and prostate cancer. Available at: https://prostatecanceruk.org/prostate-information-and-support/risk-and-symptoms/black-men-and-prostate-cancer
- Cancer Research UK (2025) Risks and causes of prostate cancer. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/risks-causes
- UK National Screening Committee (2026) Prostate cancer: UK NSC screening recommendation. Available at: https://view-health-screening-recommendations.service.gov.uk/prostate-cancer/
- GOV.UK (2026) Equality impact assessment: introduction of a targeted prostate cancer screening programme. Available at: https://www.gov.uk/government/publications/prostate-cancer-screening-equality-impact-assessment/equality-impact-assessment-introduction-of-a-targeted-prostate-cancer-screening-programme
- European Association of Urology (2026) EAU Guidelines on Prostate Cancer: Diagnostic Evaluation. Arnhem: EAU Guidelines Office. Available at: https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation
- NHS (2025) Symptoms of prostate cancer. Available at: https://www.nhs.uk/conditions/prostate-cancer/symptoms/
- National Cancer Institute (2024) BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet. Available at: https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet
- NHS England (2025) Hundreds of people at increased cancer risk identified by new NHS BRCA testing programme. Available at: https://www.england.nhs.uk/2025/01/hundreds-of-people-at-increased-cancer-risk-identified-by-new-nhs-brca-testing-programme/
- NHS Jewish BRCA Testing Programme (no date) The NHS Jewish BRCA Testing Programme. Available at: https://www.nhsjewishbrcaprogramme.org.uk/
- Castro, E. et al. (2013) ‘Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer’, Journal of Clinical Oncology, 31(14), pp. 1748–1757. Available at: https://pubmed.ncbi.nlm.nih.gov/23569316/
- Pritchard, C.C. et al. (2016) ‘Inherited DNA-repair gene mutations in men with metastatic prostate cancer’, New England Journal of Medicine, 375, pp. 443–453. Available at: https://pubmed.ncbi.nlm.nih.gov/27433846/
- Mateo, J. et al. (2024) ‘Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and/or BRCA2 in the PROfound trial’, Journal of Clinical Oncology, 42(5), pp. 571–583. Available at: https://pubmed.ncbi.nlm.nih.gov/37963304/
- Bancroft, E.K. et al. (2026) ‘Targeted prostate cancer screening in carriers of BRCA1 or BRCA2 pathogenic germline variants detects clinically relevant disease: 5-year results from the IMPACT study’, European Urology, 89(5), pp. 457–468. Available at: https://pubmed.ncbi.nlm.nih.gov/41714267/
- GOV.UK (2026) Major expansion of research and treatment for prostate cancer. Available at: https://www.gov.uk/government/news/major-expansion-of-research-and-treatment-for-prostate-cancer
- NHS (2023) Blood in urine. Available at: https://www.nhs.uk/symptoms/blood-in-urine/
- NHS (2025) Enlarged prostate. Available at: https://www.nhs.uk/conditions/enlarged-prostate/
- NHS (2026) Back pain. Available at: https://www.nhs.uk/conditions/back-pain/